TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers found that levels of 16 blood molecules linked to brain aging and dementia risk varied across menopause stages. In older women, higher levels of the proteins were associated with poorer cognitive outcomes and, in the largest cohort, a modestly greater risk of Alzheimer’s dementia over 16 years; the study does not show that menopause causes the disease.
Researchers from UC Santa Barbara, UC San Francisco and partner institutions have identified 16 blood molecules whose levels change across the menopause transition and are associated with measures of brain aging and dementia risk. The Nature Medicine study links higher levels of these proteins to poorer cognitive outcomes in older women, but it does not establish that menopause causes Alzheimer’s disease.
The team used advanced proteomic analysis to examine thousands of proteins in women at premenopausal, perimenopausal and postmenopausal stages in the Healthy Aging Study, a project examining brain and cognitive function in midlife. The proteins that changed included molecules involved in inflammation and neuronal processes, as well as proteins associated with Alzheimer’s disease.
The researchers reported that these protein shifts tracked more closely with a participant’s menopause stage than her exact age. They then checked the pattern in a separate UK Biobank dataset of more than 2,800 women, where menopause was also associated with molecular signatures of accelerated aging across multiple organ systems.
To examine links with later brain health, the authors analyzed four independent cohorts totaling nearly 12,000 older women. Higher levels of the identified “risk” proteins were associated with poorer cognitive outcomes. In the largest cohort, the protein signature was associated with a modestly higher risk of developing Alzheimer’s dementia over the following 16 years. These findings are associations, not proof that the proteins or menopause cause dementia.
Menopause as a Midlife Research Window
The findings offer researchers a way to investigate how midlife biological changes may relate to brain health years later. Menopause is often studied as a reproductive transition, but the paper’s results point to changes in blood proteins linked to processes in several parts of the body. Mapping those changes could help scientists identify which biological patterns warrant further study.
The research team says its longer-term goal is to develop a blood test that could help estimate dementia risk, in a way broadly comparable to how cholesterol measurements inform assessment of heart disease risk. That is a research aim, not a test currently established by this study. If future work validates a reliable marker, it might help identify people who could benefit from prevention research or closer monitoring during midlife.
The results do not mean that most women will develop Alzheimer’s. Senior author Kaitlin Casaletto said the findings highlight menopause as a possible period for studying when brain resilience or vulnerability may take shape. Whether interventions during this period can change later outcomes remains unproven.
Popular right now
Vitamix Propel Series 510 Professional-Grade Blender, 3 Programs, Black
Shark HydroVac MessMaster Cordless Wet Dry Vacuum and Mop Combo, AW261
Breville BES870XL Barista Express Espresso Machine, Brushed Stainless Steel
As an affiliate, we earn on qualifying purchases.
How Researchers Tested the Protein Pattern
The study, led by Madeline Wood Alexander of Sunnybrook Research Institute and Rowan Saloner and Kaitlin Casaletto of UCSF, combined protein measurements from midlife participants with data from older women in separate cohorts. Collaborators included researchers at UCSB, UCSF, Stanford University, the University of Toronto and other institutions. The paper appeared in Nature Medicine under the title “Blood proteomics of menopause map to brain aging and dementia risk.”
Using multiple datasets allowed the researchers to check whether the menopause-related protein pattern appeared beyond the initial study group and whether it was associated with later cognitive outcomes. The UK Biobank analysis included more than 2,800 women; the four older-women cohorts together included nearly 12,000. These analyses strengthen the evidence for an association, but they do not replace studies that follow the same women repeatedly through menopause and later life.
Emily Jacobs, a UCSB professor of psychological and brain sciences, said that women spend roughly one-third of their lives after menopause, while biological links between the transition and later brain health remain poorly understood. The work was supported in part by the Ann S. Bowers Women’s Brain Health Initiative, Wellcome Leap, the National Institutes of Health and the Noyce Trust.
“Menopause is not an isolated reproductive event. It is a whole-body biological transition.”
— Emily Jacobs, professor of psychological and brain sciences at UC Santa Barbara
Causation and Clinical Use Remain Unclear
The study does not show that menopause causes Alzheimer’s dementia, nor that the identified proteins cause cognitive decline. The researchers cautioned that the clinical meaning of individual Alzheimer’s-related protein changes measured in midlife is still uncertain, and most women do not develop Alzheimer’s disease. The reported increase in risk was described as modest and appeared in the largest of the older-women cohorts.
Researchers also need to establish how protein changes unfold alongside hormones, menopause symptoms and brain health over time. The cohort analyses cannot by themselves determine whether menopause-related changes precede later outcomes, reflect other influences, or help explain them. No validated clinical blood test or effective menopause-timed dementia intervention was reported as a result of this work.
Longitudinal Menopause Study Planned
The authors say longitudinal studies following the same women through the menopause transition are needed to track hormones, proteins, symptoms and brain health as they change. UCSB’s team and collaborators are launching the Longitudinal Menopause Project and are recruiting researchers. The project is intended to address a central limitation of the current evidence: the need to observe biological changes and health outcomes in the same people over time.
Further research will need to test whether the protein signature can predict outcomes reliably in different populations and whether it adds useful information beyond existing risk factors. The current study’s findings identify a direction for that work; they do not yet establish when or how clinicians should use the proteins in care.
Key Questions
What did the study find?
Researchers identified 16 blood molecules whose levels changed across menopause stages. Higher levels of the proteins were associated with poorer cognitive outcomes in older women and, in the largest cohort, a modestly higher risk of Alzheimer’s dementia over 16 years.
Does this prove menopause causes Alzheimer’s?
No. The authors explicitly cautioned that the findings do not show that menopause causes Alzheimer’s. The reported links are associations and do not establish cause and effect.
Is there a blood test based on these findings?
No clinical test was established by this study. The researchers said developing a blood test to help estimate dementia risk is a long-term research goal.
What research is planned next?
The study team is launching the Longitudinal Menopause Project, which aims to follow changes in hormones, proteins, symptoms and brain health over time. The authors say tracking the same women through menopause is needed to clarify how these factors relate.
Source: news-medical.net
